This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Sugita, Y. Articles by Monden, M. Search for Related Content PubMed PubMed Citation Articles by Sugita, Y. Articles by Monden, M.

NY-ESO-1 Expression and Immunogenicity in Malignant and Benign Breast Tumors

Departments of ¹ Surgery and Clinical Oncology and ² Surgical Oncology, Graduate School of Medicine, and ³ Department of Pathology, School of Allied Health Medicines, Osaka University, Osaka, Japan; ⁴ Department of Immunology, Okayama University Graduate School of Medicine and Dentistry, Okayama, Japan; ⁵ Ludwig Institute for Cancer Research, New York Branch at Memorial Sloan-Kettering Cancer Center, New York, New York; and ⁶ Department of Surgery, Hyogo Prefectural Nishinomiya Hospital, Hyogo, Japan

NY-ESO-1 is a cancer/testis antigen expressed in normal adult tissues solely in the testicular germ cells of normal adults and in various cancers. It induces specific humoral and cellular immunity in patients with NY-ESO-1-expressing cancer. The aim of this study was to determine the frequency of NY-ESO-1 mRNA and protein expression in malignant and benign breast tumors. NY-ESO-1 mRNA expression was detected by conventional reverse transcription-PCR and real-time PCR, and that of the protein expression by immunohistochemistry and Western blot analysis. Expression of NY-ESO-1 mRNA was detected in 37 of 88 (42%) cancer specimens, whereas that of the NY-ESO-1 protein was detected only in 1 mRNA-positive specimen. In the latter case, expression level of NY-ESO-1 mRNA relative to that in the testis was relatively high (75% of testicular expression) and to the other among breast cancer specimens. In benign breast lesions, 21 of 31 (68%) specimens expressed low levels of NY-ESO-1 mRNA. In 1 case of fibroadenoma, NY-ESO-1 mRNA was 8% of the testicular level, and protein was detected by Western blot analysis. Only 1 breast cancer patient had detectable antibody at time of surgery, which disappeared within 2 years. Tumor specimen from this patient was both NY-ESO-1 mRNA and protein positive, and NY-ESO-1-specific CD8 T cells were detected in this patient by IFN- enzyme-linked immunospot assay using NY-ESO-1 recombinant adeno and vaccinia virus. A higher rate of NY-ESO-1 expression was noted in breast cancer with high histological grade and negative hormone receptor status, suggesting NY-ESO-1 as a potential tumor antigen for immunotherapy in patients with breast cancer and poor prognosis.

This article has been cited by other articles:

				A. Grigoriadis, O. L. Caballero, K. S. Hoek, L. da Silva, Y.-T. Chen, S. J. Shin, A. A. Jungbluth, L. D. Miller, D. Clouston, J. Cebon, et al. CT-X antigen expression in human breast cancer PNAS, August 11, 2009; 106(32): 13493 - 13498. [Abstract] [Full Text] [PDF]

				D. Kanojia, M. Garg, S. Gupta, A. Gupta, and A. Suri Sperm-Associated Antigen 9, a Novel Biomarker for Early Detection of Breast Cancer Cancer Epidemiol. Biomarkers Prev., February 1, 2009; 18(2): 630 - 639. [Abstract] [Full Text] [PDF]

				M. Lacroix Significance, detection and markers of disseminated breast cancer cells Endocr. Relat. Cancer, December 1, 2006; 13(4): 1033 - 1067. [Abstract] [Full Text] [PDF]

				R. B. Parmigiani, F. Bettoni, M. D. Vibranovski, M. H. Lopes, W. K. Martins, I. W. Cunha, F. A. Soares, A. J. G. Simpson, S. J. de Souza, and A. A. Camargo Characterization of a cancer/testis (CT) antigen gene family capable of eliciting humoral response in cancer patients PNAS, November 28, 2006; 103(48): 18066 - 18071. [Abstract] [Full Text] [PDF]

				Z. Varga, J.-P. Theurillat, V. Filonenko, B. Sasse, B. Odermatt, A. A. Jungbluth, Y.-T. Chen, L. J. Old, A. Knuth, D. Jager, et al. Preferential Nuclear and Cytoplasmic NY-BR-1 Protein Expression in Primary Breast Cancer and Lymph Node Metastases. Clin. Cancer Res., May 1, 2006; 12(9): 2745 - 2751. [Abstract] [Full Text] [PDF]

				F. van Rhee, S. M. Szmania, F. Zhan, S. K. Gupta, M. Pomtree, P. Lin, R. B. Batchu, A. Moreno, G. Spagnoli, J. Shaughnessy, et al. NY-ESO-1 is highly expressed in poor-prognosis multiple myeloma and induces spontaneous humoral and cellular immune responses Blood, May 15, 2005; 105(10): 3939 - 3944. [Abstract] [Full Text] [PDF]